

FIRST FACE TO FACE MEETING OF THE UHC2030 WORKING GROUP ON SUSTAINABILITY, TRANSITION FROM AID AND HEALTH SYSTEM STRENGTHENING

30-31 March 2017 Geneva, Switzerland

INTRODUCTION

The International Health Partnership for UHC2030 (UHC2030) was established last year. The partnership is cohosted by WHO and the WB and work facilitated by a small secretariat. The objectives of UHC2030 are:

Objectives of IHP for UHC 2030

- 1. Contribute to improved coordination of HSS efforts for UHC at global level, including synergies with related technical networks
- 2. Strengthen multi-stakeholder policy dialogue and coordination of HSS efforts in countries, including adherence to IHP+ principles and behaviors in countries receiving external assistance
- 3. Contribute to accountability for progress towards HSS and UHC that contributes to a more integrate approach to accountability for SDG3
- 4. Build political momentum around a shared global vision of HSS for UHC and advocate for sufficient, appropriate and well-coordinated resource allocation to HSS

Sustainability health system strengthening and transition from external financing was identified as a topic where the new partnership might add value by facilitating linkage and synergy of ongoing work streams. A UHC 2030 working group was subsequently agreed to be set up and included in the work plan approved by the UHC2030 transitional Steering Committee in the December 2016.

The first face to face meeting of the new UHC2030 working group on Sustainability Transition from aid and health system strengthening was held 30-31st of March. The meeting was chaired by Midori Habich former Minister of Health in Peru and Kara Hansen Professor of health system economics LSHTM. The aims of the meeting were

1. Present and discuss some of the major ongoing work related to transition planning

2. Map out priority areas, key outputs and products for inclusion into a work plan for the working group on transition

Membership of the working group	Aim:
 IHP for UHC2030 hosting organiz WB WHO 	To explore roles, responsibilities and opportunities for collaboration among DPs, expert networks and countries to
 Countries: South Africa, Indones Kenya, others tbc 	interventions with financial protection, in countries transitioning
 Bilateral: EC, Japan, Germany, U DFID, others 	SAID, Australia, from aid
• GAVI, GF,	
BMGF	
Civil society	
 Academia /think tanks (John Ho R4D, Centre for Global Developr 	

EXCECUTIVE SUMMARY

Findings from a rapid background mapping; - key messages

To facilitate discussions in this first meeting a rapid background mapping of work on transition supported by the working group members had been undertaken. Some findings included:

- Diversity of definitions and understanding of "transition concept" among working group members.
- **"Sustainability"** definitions are also varied but most tend to have a focus on increased coverage and health outcomes/impact
- Limited work on effects of **multiple exits or transitions** in one country
- Limited evidence of the **effectiveness of transition policies over time** across programs focusing on the whole health sector.
- **Evolving consensus** to work towards a focus on "sustained coverage of priority interventions in the sector" rather than focus on "programme sustainability".
- **Transition provides opportunities** and entry point to identify what health system strengthening is needed (what to continue, where to integrate and adapt systems to increase efficiency)
- Limited advocacy on UHC at country level and political engagement on implications of sector wide transition underdeveloped.
- Recognition of the **importance of strengthening institutions and capacity** and that this takes time, but not always clear how this translates at country level by the various partners.

Feedback from the countries - key messages

- There are multiple transitions from external finance ongoing with multiple transition assessments and there is need for a more orderly process. Countries are interested in how to use the resources in a more efficient manner that would benefit the population as a whole and would like to learn from other countries like Thailand and Estonia on their progress towards UHC. For transition countries are interested in a more coordinated approach led by government, partnerships for capacity strengthening and as well as means of strengthening UHC monitoring accountability and advocacy.
- Generally we can say that donor priorities need to follow country priorities but in some instances
 external funding may help convince government on certain priorities e.g. of work for marginalized
 groups. Low cost sharing can increase the risk of compromising cost efficiency. Governance needs to
 involve those expected to continue work after external finance ends. Capacity of the recipient country is
 most important and sustainability should be regarded as the ability to achieve the agreed health
 system objectives.
- For many countries main issues related to transition from external finance are not financial but rather related to the value of technical assistance, opportunities for cross country learning on UHC, and advocacy opportunities for UHC. Technical capacity and national systems need to be continuously improved and there is need to build mechanisms in relation to transition that will ensure this. Another important issue is the ability of partners to work with non-state actors e.g. for HIV. There are currently no regulatory frameworks to cater for financing non state actors within the public health system. For long term sustainability capacity at the district level can be critical, ensuring minimum standards, program and managerial capacity.

 Transition and sustainability is first of all a matter of national ownership and therefore the Government would really like to be in the driving seat. These processes can be successful only if all stakeholders become part of them including different line ministries and sectors, civil society, providers both public and private and above all citizens concerned and all of these actors push hard for health for all rather than single programs. There is need for accountable leadership to coordinate all these efforts, design an orderly transition process with emphasis on strengthening the capacity of institutions and optimally linking with the wider system.

Key messages - Concepts and unit of analysis-

- Transition away from donor financing needs to be viewed in the context of the overall health financing, macro-fiscal, political, and institutional dynamics within a country. On average, the critical issue in most transition countries will not be the availability of funds. Rather more attention needs to be paid to how all funds are actually allocated and used in the system. Even in those countries with resource constraints, a differentiated transition financing strategy is not justified. Rather all countries should work to diversify and strengthen domestic resource mobilization and improve efficiency to get more from their health spending. Doing so will involve policy interventions that are tailored to each country's specific context. Understanding the macro-fiscal context in terms of willingness and ability of governments to increase public financing for health will be critical.
- The challenges faced by countries that will undergo transition go well beyond financing and pertain to
 how donor support has evolved. The MDG era of donor financing resulted in a verticalization of health
 programs focused in large part on specific diseases or interventions and resulted in separate plans,
 budgets, funding, procurement, and other systems by program or donor. The SDGs face the same risk,
 unless opportunities are seized to build UHC as an umbrella, moving away from silos to a stronger focus
 on efficient use of resources and increasing tax revenues. As donor support declines, this fragmented
 organizational approach will be left behind in countries and it is therefore the responsibility of partners
 to support ways of mitigating resulting inefficiencies.
- UHC brings a system-wide lens that is needed to tackle the challenges of related to sustainability and transition. It stresses that all programs and priority interventions fall within the overall health system and are part of coverage objectives. Therefore, the discussion around transition focuses on sustaining increased effective coverage of priority interventions towards UHC. This perspective is needed because while specific health programs might be well-run, if they duplicate functional responsibilities (e.g. contracting with providers, procurement systems, etc) they impose high costs on the system as a whole. It is important to develop a consensus among countries and partners on this point the unit of analysis should be the system and not a specific program or disease.
- Focus should be strengthened on how incentives are established at the design phase of any interventions. Institutional frameworks can be at odds with stated policy objectives. There is need to (re)focus funding early to strengthen underlying systems and for financing develop a better understanding of constraints and enablers for integrating priority services into basic benefit packages.
- Transition provides a political opportunity. Collective financing for health is driven by taxpayer's choices and citizen voice for health. Efficiency on the other hand is driven by systems of accountability. The latter includes among others regulatory and legal frameworks that help govern public financial management, rights and entitlements, procurement, accreditation etc. For transition support

strengthening governance capacity of the Ministry of Health, sometimes weakened by parallel governance structures is central. In transition countries strengthening national institutions is at the core of health system strengthening.

Scope of work for the group as per TORs

- Build consensus around core issues and objectives in response to the transition from aid, exploring revenue and health system efficiency considerations, as well as approaches to strengthening accountability for results.
- **Develop guidance and principles for good practise** pertaining to countries transitioning from ODA support, with regard to financial, programmatic and capacity issues, including but not limited to e.g. how to develop country-specific transition plans to balance the transition schedules of multiple funding partners.
- Explore the types of reforms and investments needed to support an effective transition process, particularly in relation to building strong and unified underlying support systems, such as for procurement, supply chain, information, as well as capacity for evidence informed priority setting processes.
- **Define an annual work plan** for the group, outlining key outputs and products and help convene parties to review progress.

Suggested Activities and potential role for the group:

MAPPING COUNTRY EXPERIENCE

- Collect country experience during transition to inform transitional approaches and behaviours (e.g. country case studies)
- The group could build on the mapping done for this meeting and select a subset of countries and **do mappings of transition experiences from country perspectives**. The issues arising from this should inform the operational planning for the group

IDENTIFYING MAJOR PRESSURE POINTS

- Contexts vary widely between countries, perhaps the group can think of classifying the type of issues most pertinent, as these will vary widely depending on context, UMIC and LIC etc
- The group could develop **an overview of the main pressure points** related to external finance transition and sustaining coverage of priority interventions and help organize work-streams around addressing these.

BUILD CONSENSUS ON CORE ISSUES

- Help forge a consensus on core concepts including the correct framing for "sustainability question" pushing the technical agenda for better understanding of the guiding principles and core issues.
- This group could have a role to **push for appropriate design of external finance,** that takes into consideration incentives for domestic budget response and fungibility (from the perspectives of the system rather than the program.)
- Work on **ways of building national capacity** for comprehensive engagement between ministry of finance and health (not many approaching MOF with separate disease program issue) and a focus on fundamentals rather than undue fascination with innovation and quick fixes.
- The group could also help facilitate a consensus on areas where more conceptual clarity is needed e.g. public and personal health services and harmonization of incentives and advocate for importance of capacity building and work on strengthening underlying subsystems.

• To develop and agree a glossary of key terms in relation to transition.

DEVELOPMENT OF LESSON LEARNING AND GUIIDANCE

- The group should **develop guidance and best practise** on how successful transition should happen at country level. What are some of the barriers and enabling factors for the focus to be on the system as a whole and sustaining coverage of priority interventions?
- Share country lessons and develop guidance and good practise on social contracting.
- Facilitate better support to countries in improving planning for transition, at the national level, as countries are in some cases falling off a cliff, and preparation is often not sufficient. There are also opportunities to **develop principles of more harmonized way of working at country level** as multiple assessments are ongoing. There is also need to provide stronger focus on what happens after assessments, best practises on strengthening institutional capacity.
- This group should help look at thresholds and graduation policies
- Share available work on experiences of integrating previously ODA supported areas e.g. immunization and TB into BBP incentives and disincentives and understanding the needed sequence of steps to strengthen institutional capacity.
- The group should help link countries together for **peer to peer learning** on transit on from external finance and the interface of this and moving forward towards UHC.
- The group may have a role in highlighting **gaps** in health system support and help effort to streamline this.

JOINT ACTION AT COUNTRY LEVEL

In terms of coordination among partners -a lot of coordination happens at the global level – however this is often
not reflected at country level. Therefore the recommendation is to move forward to identify countries for joint
action and try and provide assistance not only on technical issues but also on political influence and making things
happen.

TECHNCIAL AND POLITICAL INFLUENCING

- The group has a role in **linking** the work on Sustainability and transition to the **higher political level for more** effective follow up at institutional level among the different actors
- The group could add value by helping **bring the "program" and "system" communities together**, and influence the political aspect of needed changes both at international and national levels
- Share learning from country experience e.g. generating political priority for health in complex transitions
- Identifying new and common technical issues for learning e.g. integration, efficiency

ADVOCACY

• There is a perceived **lack of advocacy for health systems** as opposed to advocacy for program or specific disease, and the group might have as a subtopic to focus on ways of stepping this up. Civil society has contributed significantly on advocacy for various disease control efforts but their engagement on HSS horizontal issues and community strengthening has been less supported and hence weaker.

AREAS SUGGESTED THE GROUP WILL NOT WORK ON

- Harmonising all tools for assessment and transition
- New tools
- Studies without related capacity building
- Build pool of experts on transition

DAY 1: TRANSITION FROM EXTERNAL FINANCE AND COUNTRY PERSPECTIVES

1. Discussion on ongoing work related to transition

Findings from a rapid background mapping; Veronica Walford and Clare Dickinson, IHP for UHC2030 consultants

An overview was provided of the rapid mapping of group member policies and definitions on transition. This highlighted diversity of definitions and understanding of *transition* among working group members. *Sustainability* definitions are also varied but most tend to have a focus on increased coverage and health outcomes/impact. Policies of working group members on transition also varied. Global Health Initiatives (GHI) have formal policies that include objective criteria and roadmaps for transition with country guidelines in place. GF and GAVI also have fairly long timelines for transition, growing domestic finance share, regular monitoring and recognition of the need to embed transition early on in program design. Their policies also underline alignment with health plans and the need to fund the health sector overall. Bilateral partners have less formal policies; triggers for transition can include various factors not just funding ability. When bilateral funding end other modalities for engagement through pooled TA and centrally managed funds continue. WB and WHO tend to have a sector perspective on transition and focus on the bigger picture.

For majority of members sustainability means increased effective coverage of priority interventions to progress to UHC rather than sustainability of particular programs. Health financing transition work focuses on improving efficiency while ensuring service coverage and reducing out of pocket (OOP) reliance. For other members including, academia, BMGF and Civil society, transition work is a priority but explicit policies are not in place but work focuses on various analytical work and development of tools to inform policies and influence political engagement on transition. For BMGF work has focused on developing systematic transition finance mechanisms to support countries transitioning from different funding partners.

Broadly three categories of transition work can be seen; 1) program level work, e.g. preparedness and assessment tools, 2) Health system assessments and support e.g. HTA, fiscal space analysis, PFM alignment to financing systems 3) conceptual thinking and learning for policy development e.g. reviews in most cases focusing on one funding source. While there is consensus on some of the elements of a successful transition multiple tools and planning processes are sometimes required of countries sometimes in an uncoordinated way. All recognize that building capacity takes time and there is need for a system perspective but not clear if this translates into direct work on integrating and supporting systems for prioritization.

Apparent gaps include scarcity of reviews that look at multiple exits in one country and limited evidence on the effectiveness of policies over time. Advocacy on UHC at country level appears to be limited and political engagement on implications on sector wide transition is underdeveloped in many countries.

Opportunities exist to link transition to work on different parts of health system efficiency and forging collaboration across the system. There are also opportunities to develop principles of more harmonized way of working at country level and provide a stronger focus on what happens after assessments, best practises on strengthening institutional capacity.

Institutions for transition towards UHC,

Agnes Soucat: Director, Health Systems Governance and Finance, WHO

"Defining transition in which the per capita amount of external financing declines while indicators of (1) overall population and health and (2) overall access to health services do not decline"

Bill Savedoff

Data show that in LIC including in fragile states external finance constitutes about ¼ of THE, whereas in MIC this is often <5% of THE. Looking at LMIC countries where typically partners are withdrawing taking the subset of countries graduating from GF and GAVI as an example, data show that while progress can be made improving government prioritization of health, public health expenditure per capita is higher than LMIC average. Transition from external finance is therefore both about revenues and efficient use of resources. Dialogue with MOF cannot be done on a program by program basis; the focus needs to be on streamlining architecture across programs and investing in underlying systems for best results as well as effective domestic revenue generation and allocation at sector level. Critically this needs to be accompanied by efforts to strengthen institutions and processes that support and enable system efficiency and performance.

WHO articulates three categories of health system support; support to health system foundations, strengthening institutions and transformation support. The MDG era saw many vertical funding streams, with separate planning, budgeting, procurement and monitoring at times stimulating domestic fragmentation. The SDGs face the same risk, unless opportunities are seized to build UHC as an umbrella, moving away from silos to a stronger focus on efficient use of resources and increasing tax revenues for the sector. In transition countries strengthening domestic institutions is at the core of health system strengthening. Collective financing for health is driven by taxpayer's choices and citizen voice for health. Efficiency on the other hand is driven by systems of accountability. The latter includes among others regulatory and legal frameworks that help govern public financial management, rights and entitlements, procurement, accreditation etc. For transition support strengthening governance capacity of the Ministry of Health, sometimes weakened by parallel governance structures is central. This includes for example institutional capacity for HTA and strategic purchasing, systems for strengthen evidence informed policy, standard setting, and importantly implementation capacity. Evidence based comprehensive health sector strategies, developed in a participatory manner should reflect overall health system objectives integrating priority programs together with key subsectors human resources, pharmaceuticals and others.

Discussion

Citizen engagement is very important and here programs like HIV can share their experience on engaging civil society but also parliament to strengthen citizen voice. There needs to be clarity of timelines for transition and coordination between partners on this. GDP is not necessarily an ideal trigger for transition that instead should be based on performance of the system.

2. Country perspectives

Sustainability and Transition - Why? How? When? The Estonian case.

Triin Habicht, Senior Adviser to the Ministry of Health, Estonia

Estonia outlined experiences from transition from three types of external finance, a GF grant on HIV, EC structural funds focusing on infrastructure, and Norwegian grant with a focus on mental health of children.

For the GF experience the CCM as a multi-sector structure was helpful as this would have been difficult to initiate without external stimulus. Some of the practises related to linking the procurement closely to the national health plan action plan, more rigorous monitoring e.g. through periodic surveys also helped strengthen parts of national systems. After the funding ended the existence of a multisectoral HIV strategy accompanied by a multi sector agreement with the various ministries involved was important, and WHO follow up and reviews of the strategy after transition were also helpful. Last but not least funding ended prior to the finance crisis and political commitment and favourable conditions to overtake financial commitments existed. EC funds were mostly used for infrastructure investment and perhaps opportunities were lost to direct the funding to restructure service delivery models but this may also need different type of investment to an extent. A small part was used for PH services and this helped raise the profile of these services also post finance crisis. Lastly the Norwegian funds, helped make the political case for a challenging area and stimulated cross sector work.

Generally we can say that donor priorities need to follow country priorities but in some instances external funding may help convince government on certain priorities e.g. of work for marginalized groups. Low cost sharing can increase the risk of compromising cost efficiency. Governance needs to involve those expected to continue work after external finance ends. Capacity of the recipient country is most important and sustainability should be regarded as the ability to achieve the agreed health system objectives.

Discussion:

Some generic lessons can be drawn from the recent financial crisis where many countries had to cut public financing for health. One aspect was the interphase between health financing and institutional arrangements. In times of financial crisis strong finance institutional arrangements serve to protect core services whereas those outside such systems e.g. public health services were harder hit as they were in the general budget. How can we offer that protection? Countries that were already running a budget deficit at the start of the finance crisis were harder hit by the crisis but countercyclical measures would have helped.

How funds flow can impact how hard different services are hit at times of finance crisis, Greece for example did blanket cuts across services hitting small separately funded services like needle exchange hard, triggering an IDU driven surge in incidence of HIV infections. So in thinking about sustainability of priority interventions the structure of public financing systems matters.

Moving towards UHC, the role of external finance for health in South Africa

Aquina Thulare, Technical Specialist, Health Economics, National Health Insurance, South Africa Nellie Malefetse, Director of International Relations for Health, South Africa

Total health expenditure as % of GDP in South Africa is relatively high or 8.8% (2014). Roughly half are public funds and half private. Government allocation as part of overall government funding is also quite high. GINI coefficient reflecting inequity is 0.69 or among the highest in the world. Most of the private funding covers only 15% of the population. South Africa is an UMIC and external finance constitutes less than 1.4% of THE, and 2.9% of public finance for health, the large majority of which is concentrated for HIV. The burden of NCDs has for some years exceeded communicable disease and the country has four colliding epidemics, NCD, HIV/TB, RHMNCH, and violence and injury.

Development coordination structures are in place is South Africa but fragmentation persists. For some areas there is a multiplicity of partners, for example information systems. If the Ministry is not watching closely there is a risk of fragmentation, at times partners have gone directly to provinces and interventions supported have not had inter-operability with other key parts of the system resulting in poor use of valuable resources.

South Africa is an UMIC and this triggers many partners to shift from offering grants to loans. There are multiple transitions from external finance ongoing with multiple transition assessments and there is need for a more orderly process. South Africa is interested in how to use the considerable resources in a more efficient manner that would benefit the population as a whole and would like to learn from other countries like Thailand and Estonia on their progress towards UHC. For transition there is interest in better ways of coordinating, partnerships for capacity strengthening as well as means of strengthening UHC monitoring accountability and advocacy.

Discussion

Thinking about ways efficiency could be improved, South Africa is in the process of finance reforms sequencing different steps including benefit design. Health technology assessments have also been carried out, but there is need to strengthen technical capacity at governmental level. For revenue raising both VAT changes and sin taxes have been discussed but earmarking is not looked well upon at the national level.

Transitioning externally funded health programs -Country Experience Indonesia

• Pungkas Bahjuri Ali, Director of Community Health and Nutrition, Ministry of National Planning, Indonesia

Indonesia has been a middle income country for several years and is projected to become a UMIC within next two years. National revenues and expenditures were 17% of GDP in 2013 a small proportion both in regional and income group 4context. THE and PHE as % of GDP are both low (3.6% and 1.1% respectively) and health is only allocated 5.9% of the national budget. OOP were 45% in 2014 but have reduced from 55% in 2010. The majority of revenues are raised at central level while more than 50% of expenditures occur at district level. Intergovernmental transfers are complex and in some cases fragmented. There is a large informal sector and the system is highly decentralized.

The Indonesian Health Insurance System (JKN) was established in 2015. Since then coverage has increased from 68million to 179million (69% of the population). The aim is to expand coverage to the whole population by 2019. The JKN is the largest single payer system in the world.

External finance constitutes a minimal part of THE, but reliance on external funds within particular programs like HIV, TB, Malaria and Immunization can be between 40-60% - although this is reducing. Several partners are phasing out. Main issues related to transition from external finance are not financial but rather related to the value of technical assistance, opportunities for cross country learning on UHC, and advocacy opportunities for UHC. Technical capacity needs to be continuously improved and there is need to build mechanisms in relation to transition that will ensure this. Another important issue is the ability of partners to work with non-state actors e.g. for HIV. There are currently no regulatory frameworks to cater for financing non state actors within the public health system. For long term sustainability capacity at the district level is critical, ensuring minimum standards, program and managerial capacity.

Indonesia is working with the WB on a transition strategy through support from a multi donor trust fund. Transition should be about increasing coverage of priority interventions. There is need for advocacy to MOH but also MOF and other Ministries to increase fiscal space for health. To sustain coverage for HIV/TB /Malaria there is need to create regulation that enables contracting of non-state actors. There is also need to integrate activities into public finance planning and budgeting processes and to the health insurance package, explore public private partnerships and last but not least improve efficiency.

Discussion

Our system is decentralized and strengthening district capacity is an important priority. We have had externally supported pilots which have been useful, but they have been well resourced with staff and capacity so applying lessons for scale up to the wider system that does not have the same type of resources has been difficult.

Indonesia is an example of a country where it is not the funding that is an issue but much more how the funding flows and the transition towards social health insurance that is expanding. A need to understand better what should be done to better incentivise previously donor supported areas e.g. immunization integration within such systems.

Kenya - Leadership, Multiple Assessments, Fragmentation in Health Sector Planning

Regina Ombam, Deputy Director, HIV Investments, National Aids Council, Kenya

The annual number of HIV infections in Kenya peaked in 1995 and has since been reducing. Around 70% of funding for the HIV response is external, 16% from public sources and 14% from private sources. PEPFAR constitutes the largest share of the 70%. A possible donor withdrawal for Kenya is a matter of both generating adequate domestic revenue and building the appropriate mechanisms and institutions for smooth transition and sustainability.

The National AIDS Council in Kenya has done detailed analysis of possible sources for increased domestic financing as well as options for channeling of funds and purchasing of services, including the potential to set up a separate HIV fund. This was met with quite some resistance from different directions, both at sector level and from other programs.

Although Kenya is not expected to transition from external aid for its HIV response in the near future, the country has seen a plethora of offers by different partners to help the country with planning for its transition and sustainability – in most cases these offers are not coordinated at all among partners and are being proposed without prior discussions with the government.

For the Government of Kenya transition and sustainability is first of all a matter of national ownership and therefore the Government would really like to be in the driving seat. These processes can be successful only if all stakeholders become part of them including different line ministries and sectors, civil society, providers both public and private and above all citizens concerned and all of these actors push hard for health for all rather than single programs

There is need for accountable leadership to coordinate all these efforts, design an orderly transition process with emphasis on strengthening the capacity of institutions and optimally linking with the wider system. We look to WHO and WB to help us with the linkage to the national level system and strengthening institutions.

Discussion

There were hopes that a new health financing strategy would help get everyone away from competing for their own earmarking, GFF was supposed to help move in this direction but progress has been slower than expected.

There is need to get better at thinking through political sequencing of reforms, often times there is an overemphasis on assessments and studies but too little thinking about a strategy for implementation.

The elephant in the room is that aid can be rent seeking, with vested interests. This underscores the need to focus on domestic finance and that a health finance strategy needs continued engagement and cannot be a zoom in and out activity.

Partner and regional perspectives

Some of the first work on collaboration among stakeholders on transition and sustainability was started by UNAIDS and WB through the economic reference group on HIV (ERG). The experience and lessons learned from this group can give useful insights on the scope of work and modes of working for this working group.

Such groups comprised of a mix of academics and professionals, from different agencies and countries can serve as important forums for different stakeholders coming together, discuss innovative ideas and develop a common understanding and coordinate to the extent possible. A mechanism for coordinating transition efforts among UNAIDS, GFATM, PEPFAR/UNAIDS was born out of ERG and this cooperation is continuing even after the end of the ERG

With the right mix of stakeholders around the table, influencing policy is possible – as has been the case e.g. with UNAIDS strategy for positioning HIV into the UHC efforts or GFATM transition and sustainability policy. Participation of country representatives in these groups is of paramount importance – they critically bring experiences and country insights and can also take ideas generated and explore their appropriateness and adaptation within country policies and strategies.

Finally these groups can be important communities of practice that can provide tailored technical assistance to countries when needed. In terms of coordination among partners -a lot of coordination happens at the global level – however this is not always reflected at country level. Therefore the main recommendation to move forward is to identify countries for joint action and try and provide assistance not only on technical issues but also on political influence and making things happen.

The WHO PAHO region is very diverse with a wide range of economic contexts including some of the BRICs like Brazil. For several countries fiscal capacity is low with public expenditure from GDP considerably lower than in the EC for example. Fiscal prioritization is also low with many countries falling below the 15% expenditure level on health from public budgets. Very few countries in the region have above 6% of GDP allocated to health and only three are in Latin America and Caribbean (LAC). OOP is 32% of total health expenditure on average and only 6 countries are below 20% OOP as part of THE. With regards to work on sustainability and transition some work has been done on the different dimensions of sustainability and examining some determinants of sustainability but have not developed a theoretical framework. WHO has supported fiscal space studies in 14 countries and some of the findings highlight that formalizing the economy has the largest potential to increase fiscal space followed by VAT changes. Moving forward on sustainability will include increasing focus on prevention and early detection of chronic disease, strengthening first level of care, increase in public funds for health, promoting pooled financing and reducing incidence of catastrophic payment as well as supporting integrated service provision and improving efficiency.

DAY 2: SUSTAINABILITY, TRANSITION, UNIT OF ANALYSIS AND PRIORITY AREAS OF WORK

3. Rethinking the discussion on sustainability and transition

Financial sustainability challenges in transitioning from external sources of financing

• Ajay Tendon Lead Economist World Bank

A WB run multi-donor trust (MDTF) fund was launched 1.5 years ago. As countries develop economically the share of external finance naturally reduces. The fund focuses on a selection of LMIC in East Asia and the Pacific but within this group there is still huge diversity in dependency on external finance ranging from close to 25% to 1% of THE in countries like Indonesia. There are different financial sustainability implications, in some countries ODA reduces as economy grows but this can also go the other way. Secondly there is a transition towards more pre-paid pooled financing mechanisms and reduced reliance on OOP.

Transition from external finance should be considered within the context of countries moving towards UHC. Sustainability in the context of transition could be the ability to maintain or increase coverage of priority interventions after the end of support. We conceptualize programmatic aspects of transition that focus on how service delivery and governance are configured e.g. how well externally financed programs are integrated to national systems and financial aspects that focus on revenue and expenditure e.g. ability to replace external finance. Results can be monitored through current WB WHO UHC dashboard indicators that reflect various aspects of service coverage as well as financial protection.

There is also need to place transition within macro-economic context. The share of public health expenditure per capita that eventually translates into health outcomes is derived from GDP/per capita, public expenditure as part of GDP and health as part of government allocation. It is important also to look at trends and projections in economic growth over a few years. South East Asia has had robust growth in a number of countries whereas the Pacific countries covered under the MDTF have had much more fluctuations. Trends in economic growth can project the number of years it will take for the economy to double. In Myanmar this could be 10 years and clearly introduction of new taxes would therefore not be the way forward in their case whereas in other countries where doubling of the economy will take more than a 100 years things may look different. Influencing the public expenditure part of GDP this lies outside the health sector. Priority of health in government budget

also matters and how resources are prioritized among sectors, differs widely between countries ranging from 1% to 30%. In advocating for increased allocations political economy considerations are important and generally focusing on efficient spending of resources may be more effective then only focusing on advocating for government budgetary targets. Earmarked taxes are sometimes used to increase health share of the budget, social health insurance is one way of earmarking, tobacco tax another, but it is important to understand where this is going to be helpful and trends over time as the increase can diminish overtime. Dept and deficit ratio by GDP also come into play.

Thinking through sustainability and transition

• Joe Kutzin Health Financing Coordinator WHO

Transition from external finance has brought a flurry of interest in financial sustainability. WHO is well placed to play a neutral technical advisory role as WHO will not transition its support and is not a donor agency. The importance of good targeting of external finance is receiving increased focus, and various programs are preparing investment scenarios and are interested in new innovative finance or earmarked taxes. Experience however shows that the net increase in resources to health can be short lived. For example in Ghana an earmarked VAT initially increased resources for health but this effect diminished over time. Similarly in the former Soviet countries introduced earmarked payroll tax but eventually a net reduction in resource allocation to health was observed.

In thinking about the concept of financial sustainability it is important to recognize that this is not a goal per se but rather a constraint; i.e. we are trying to maximize health system goals and move towards UHC within the constraints provided by the budget. Both service coverage and financial protection vary greatly between countries with similar public health expenditure levels which underscores the importance of efficient spending. Determinants of public health spending are in part a political choice e.g. It is a Government decision how much it chooses to spend on health influenced both by public policy priorities and fiscal capacity.

When applying the concept of sustainability there should be clarity on what we are aiming to sustain. Rather than aiming to sustain a program for MCH/TB, or HIV – this should be about sustaining increased coverage of priority interventions, because programs can be well run per se but may have duplication and inefficiencies from the sector perspective and hence the aim should not be to sustain three different information systems, five procurement systems, distorted human resource incentives but - sustained coverage of priority interventions. It is important to develop a consensus among countries and partners on this point – the unit of analysis should be the system and not a specific program or disease.

Transition from external financing is a political opportunity as strengthening domestic resource mobilization and improving efficiency of health spending should be high on the agenda for countries regardless of whether they are transitioning in some way from external finance or not.

This group could have a role to push for appropriate design of external finance, that takes into consideration incentives for domestic budget response and fungibility (from the perspectives of the system rather than the program.) ways of building national capacity for comprehensive engagement between ministry of finance and health (not many approaching MOF with separate disease program issue) and a focus on fundamentals rather than undue fascination with innovation and quick fixes that sometime draws attention away from work on efficiency gains. As a multi-partner platform the group should reach out to the political level of the various institutions and build a consensus on getting the question of what we are trying to sustain right, and ensure the unit of analysis is correct. The group can also help develop a consensus on core guiding principles of health finance for UHC.

Discussion

In considering the context for transition it is important also to factor in income distribution, averages can hide differences in reliance on external finance. Absolute numbers matter also and % can be misleading. Demographic changes also come into play e.g. in some countries in Africa fertility is falling.

Countries with similar level of income can have different ratio for ODA dependency, it is important to understand what the contributing factors are. Implicit rationing often disproportionately impacts the poor.

MOH engagement with MOF on revenues can be fine, but the large gains lie in increasing national capacity to raise revenues. Social sectors could join forces to work with MOF on opportunities for revenue raising.

For the group, a key issue is support to countries in improving planning for transition, at the national level, as countries are in some cases falling off a cliff, and preparation is far from sufficient. The group should focus on ways to support comprehensive transition planning.

Cross Programmatic Inefficiencies breaking the silos

• Susan Sparkes, WHO Health Finance

This session presented work that has analysed health programs including how they are financed, governed, their use and generation of inputs to deliver priority services in the context of the system efforts to achieve outcomes. Through this an effort has been made to identify where incentives are misaligned or conceptual issues that need clarifying. Case studies from three countries are under development; Estonia Ghana and South Africa.

In Estonia a somewhat artificial divide between public health services and individual health services translates into 95% of the population being covered by an insurance fund but separate finance of TB, HIV and drug abuse services whereas in Ghana HIV and TB positive people have free NHI enrolment but TB and HIV services are explicitly excluded from the benefit package.

Policies can explicitly have integration as objectives but structure and incentives may pull in a different direction e.g. South Africa has a national policy that aims to integrate services but 20% of public health budget is earmarked for HIV conditional grant and the 12 HIV subprograms each budget separately for staff and information systems are separate for HIV, TB and the district health information system. Estonia's policy states HIV and TB services should be provided by family medicine. National Institute of Health Development (NIHD) contracts with specialists and NGO and pays specialist with fee for service arrangement to test and treat HIV, while family medicine are expected to do the same on a per capitation payment mechanism.

Transition from external finance needs to be regarded within the overall finance context, e.g. GF and GAVI push for payment of arrears in a context where NHIF has not being able to pay bills for some time. In South Africa HIV conditional grant funds have increased while no increase on general budgets has been possible.

Observations from this work highlight the importance of thinking about the incentives established at the design phase of any interventions. Institutional frameworks can be at odds with stated policy objectives. There is need to (re)focus funding early to strengthen underlying systems and for financing develop a better understanding of constraints and enablers for integrating priority services into basic benefit packages.

The group could add value by helping bring the "program" and "system" communities together, and influence the political aspect of needed changes both at international and national levels. The group could also help facilitate a consensus on areas where more conceptual clarity is needed e.g. public and personal health services and harmonization of incentives and advocate for importance of capacity building and work on strengthening underlying subsystems.

Discussion

Indeed services within the insurance fund in Estonia are protected because of the mechanism of how they are financed but the motivation to fund some parts of the services separately has also been that this has provided a good way to raise additional funds for the system. The health system and the insurance fund are a hard sell at MOF level. There is value in a mixed approach and it can provide a win win.

In South Africa high level of earmarking for HIV does indeed contribute to fragmentation of services and this in turn to a breakdown of continuity of care. Demand for attribution is then reflected in strengthened role for auditor general and increasingly inflexible systems. At the international level risk management has in some cases proven an effective way to advocate for more resources for health system work.

Populations are aging and chronic diseases and multi morbidity increasingly present the majority of the disease burden reflecting an epidemiological transition. What are the implications for continuing to have a selected set of diseases and conditions funded separately from pooled finance mechanisms?

(Re-) Building a enabling legal environment for UHC;

• David Clarke WHO Governance team

Exploring further health system sub areas in relation to UHC and transition; health laws are an important part of the enabling environment for moving towards UHC. This can be direct through legal and regulatory frameworks, e.g. procurement laws, trade law issues related to transition, laws governing health technology assessments, or laws to cover social contracting already mentioned in relation to transition. Other relevant areas include for example health insurance laws or laws pertaining to regulation of NCD risk factors like tobacco, alcohol and sugar.

Legal frameworks also form part of enabling environment for public participation in health policy processes accountability and transparency. Implementation enforcement and compliance with laws is the third area that often requires more targeted focus.

Legal infrastructure for health is therefore an important area to consider for strengthening capacity of institutions to sustain and increase coverage of priority interventions. UNDP and GF have done specific work on legal environments for TB HIV and Malaria and there may be benefit in linking this work with other efforts to strengthen legal environment of UHC and health security.

Discussion

Value added may include mapping key pressure points related to legal frameworks, transition and UHC and see if some of these could be anticipated. Experience from Eastern European work on transition highlights many issues need addressing e.g. human resource laws and various issues related specifically to HIV and TB legal environment. Health insurance laws and decentralization are sometimes in conflict and at times laws governing budgeting processes are themselves part of barriers to improving efficiency. Availability of national health lawyers is a critical element for further work on this, and capacity building in that area is important.

Towards Access 2030

• Gilles Forte WHO Medicines and Health Products Program

Pharmaceutical systems are an important area for efficiency in the health sector. The whole pharmaceutical value chain from production and marketing, selection, procurement and supply to prescribing, dispensing and medicine use – are all possible areas of efficiency gains. Many countries face a high burden of non-communicable disease and are grappling with high costs of drugs e.g. for cancer while an unfinished agenda of communicable diseases remains. Issues with access to essential medicines remain including for major communicable disease like TB HIV and Malaria. The need to strengthen regulatory systems is high on the agenda, combating counterfeit medicine but there are human and financial capacity issues. There are many actors in this sub sector and fragmentation due to verticalization. Evidence based selection and use of drugs including antimicrobials is also high on the agenda compounded by the rise in antimicrobial resistance.

Discussion

There are many issues in countries related to transition and procurement, and also some initiatives dealing with this but more efforts are needed to strengthen capacity of national institutions. Also many issue related to quality including domestic production and weak regulatory mechanisms. In thinking about complexity of fund flows within the pharmaceutical systems the question needs to be what should be done to simplify these.

Civil Society Perspectives

• Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates (remotely connected)

Civil Society has several issues to raise related to processes for transitioning away from external finance. They include the need to revisit the criteria for eligibility as the current use of GNI often does not reflect countries ability sustains and scale up services. We also believe the goal of transition needs to be clearer and criteria for the process should reflect this. There is also need for more clarity on support needs before during and after transitioning away from external finance. Social contracting is an area where more work is needed directly related to CS work in many countries. There is acknowledgement of the importance of political commitment, for addressing issues coming up in relation to transition but limited work has been done one this. For whatever reasons, countries are sometimes unaware they will be transitioning until this actually happens and critically parliamentarians are not involved. We have seen epidemics come back when support to marginalized populations is reduced. The group could add value by sharing experience at country level in supporting system level advocacy. Currently advocacy happens more by program, but there is need for more horizontal advocacy on social accountability and community mobilization.

Participant	Title and organization
Mr Pungkas Bahjuri ALI	Director of Community Health and Nutrition
	Ministry of National Planning for Development
	National Planning Agency
	Indonesia
Dr Anshu BANERJEE	Director (Global Coordination)
	Office of the Assistant Director-General, Family Women's and Children's Health World
	Health Organization
Mr Michael BOROWITZ	Head, Strategic Investments and Partnerships
	Global Fund to Fight AIDS, Tuberculosis and Malaria
Mr Michael CHAITKIN	Senior Program Officer
	Results for Development Institute
	United States of America
Dr Camilo CID	Advisor, Health Economics and Financing
	Pan American Health Organization/World Health
	Organization (PAHO/WHO)
Mr David CLARKE	Health Systems Adviser (legal)
	Health Systems Governance and Financing
	World Health Organization
Dr Santiago CORNEJO	Senior Specialist, Immunization Financing
	GAVI Alliance
Ms Corrine DURIAUX	Coordinator, Strategic Initiative on Sustainability and Transition
	Global Fund to Fight AIDS, Tuberculosis and Malaria
Dr David EVANS	Health Financing Expert
	Health, Nutrition and Population
	World Bank,
Dr Gilles FORTE	Coordinator, Essential Medicines and Health Products
	World Health Organization
Mr Mohamed GAD	Technical Analyst – Health Economics
	Institute for Global Health Innovation
	Imperial College
	United Kingdom
Dr Midori DE HABICH	Independent Consultant, Health Systems Peru
Ms Triin HABICHT	Senior Adviser to the Minister of Health
	Ministry of Health
	Estonia
Dr Kara HANSON	Professor of Health System Economics
	London School of Hygiene and Tropical Medicine
	United Kingdom
Mrs Xiao Xian HUANG	Expanded Programme on Immunization Plus
	Immunization, Vaccines and Biologicals
	World Health Organization
Mr Thomas HURLEY	Deputy Director, Multilateral Partnerships Group
	Bill and Melinda Gates Foundation
	United States of America
Dr Joseph KUTZIN	Coordinator, Health Financing
	Health Systems Governance and Financing
	World Health Organization
Ms Ariane LATHUILLE	Health Policy Officer
	Ministry of Foreign Affairs, France
	Permanent Mission of France to the UN in Geneva
MrMatthew MACGREGOR	Fund Portfolio Manager
	Global Fund to Fight AIDS, Tuberculosis and Malaria
Ms Nelly MALEFETSE	Director, International Relations

	Health Sector
	Department of Health
	South Africa
Dr Awad MATARIA	Regional Adviser, Health Economics and Financing
	WHO Regional Office in the Eastern Mediterranean
	Egypt
Dr Shin-ichiro NODA	Medical Officer
	Department of Global Network and Partnership
	National Center for Global Health and Medicine
	Japan
Ms Meghan O'CONNELL	Program Officer
	Results for Development Institute
	United States of America
Ms Regina OMBAM	Head, Strategy Development
	National Aids Control Council
	Kenya
Dr Tim POLETTI	Health Adviser
	Permanent Mission of Australia to the UN
	Switzerland
Mr Claudio POLITI	Health Adviser
	Permanent Mission of Australia to the UN
	Switzerland
Dr Matthias REINICKE	Health Sector Advisor, Europe Aid
	European Commission
	Belgium
Mr Bruno RIVALAN	IHP+ Northern Civil Society Representative
	Head, France Office
	Global Health Advocates
	France
Ms Katja ROLL	Senior Advisor – Team Leader Health Funds
	Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH
	Germany
Dr William SAVEDOFF	Senior Fellow
	Center for Global Development
	United States of America
Dr Zubin SHROFF	Technical Officer
	Alliance for Health Policy and Systems Research
	World Health Organization
Dr Agnes SOUCAT	Director Health Systems Governance and Financing
	World Health Organization
Dr Susan SPARKES	Technical Officer
	Health Systems Governance and Financing
	World Health Organization
Dr Ajay TANDON	Lead Economist
	Health Nutrition and Population
	World Bank
	United States of America
Dr Nertila TAVANXHI	Technical Adviser
	Evaluation and Economics Division
	Joint United Nations Programme on HIV/AIDS (UNAIDS)
Dr Aquina THULARE	Technical Specialist, Health Economics
	National Health Insurance
	National Health Insurance
Mrs Diana WEIL	National Health Insurance Department of Health
Mrs Diana WEIL	National Health Insurance Department of Health South Africa

	World Health Organization
Ms Clare DICKINSON	Senior Consultant
	United Kingdom
Ms Diane LE CORVEC	Consultant, IHP for UHC2030
	Health Systems Governance and Financing
	World Health Organization
Ms Marjolaine NICOD	Joint Lead, IHP for UHC2030 Core Team
	Coordinator, Health Systems Governance and Financing
	World Health Organization
Mrs Victoria PASCUAL	Team Assistant, IHP for UHC2030
	Health Systems Governance and Financing
	World Health Organization
Dr Finn SCHLEIMANN	Health Systems Advisor, IHP for UHC2030
	Health Systems Governance and Financing
	World Health Organization
Dr.Maria	Technical Officer, IHP for UHC2030
SKARPHEDINSDOTTIR	Health Systems Governance and Financing
	World Health Organization
Ms Veronica WALFORD	Senior Consultant
	United Kingdom
Dr Akihito WATABE	Health Financing Officer
	Health Systems Governance and Financing
	World Health Organization

FIRST FACE TO FACE MEETING OF THE UHC2030 WORKING GROUP ON SUSTAINABILITY, TRANSITION FROM AID AND HEALTH SYSTEM STRENGTHENING

30-31 March 2017

Hotel Beau Rivage, 13 Quai du Mont Blanc, Geneva, Switzerland

Provisional Agenda

DAY 1: TRANSITION FROM EXTERNAL FINANCE AND COUNTRY PERSPECTIVES

1. Discussion on ongoing work related to transition	
08:30-09:00	Registration and welcome coffee
09:00-09:15	Welcome and opening remarks
	 Marjolaine Nicod, WHO Coordinator for IHP for UHC2030
	 Midori de Habich, former Minister of Health of Peru, Co- Chair
	Kara Hanson, Professor of Health System Economics London School of
	Hygiene and Tropical Medicine, Co-chair
	ator: Kara Hanson
09:15-09:35	Findings from a rapid background mapping
	 Veronica Walford, IHP for UHC2030 consultant
	Clare Dickinson, IHP for UHC2030 consultant
09.35-10.00	Feedback and implications for action/next steps
05.55 10.00	
10.00-10.20	Institutions for transition towards UHC
	Agnes Soucat: Director, Health Systems Governance and Finance, WHO
10:20-10:40	Feedback and implications for action/next steps
10:40 -11:10	COFFEE BREAK
	untry perspectives
	ator: Midori de Habich
11:10-11:35	Sustainability and Transition - Why? How? When? The Estonian case
	Triin Habicht, Senior Adviser to the Ministry of Health, Estonia
11:35-12:00	Feedback and implications for action/next steps
12:00-13:00	LUNCH
13:00-13:30	Moving towards UHC, the role of external finance
	Aquina Thulare, Technical Specialist, Health Economics, National Health
	Insurance, South Africa
	Nellie Malefetse, Director of International Relations for Health, South
	Africa
13:30-13:50	Feedback and implications for action/next steps

13:50-14:10	Indonesia
	 Pungkas Bahjuri Ali, Director of Community Health and Nutrition, Ministry of National Planning, Indonesia
14:10-14:30	Feedback and implications for action/next steps
14:30-14:50	 Leadership, Multiple Assessments, Fragmentation in Health Sector Planning Regina Ombam, Deputy Director, HIV Investments, National Aids Council, Kenya
14:50-15:10	Feedback and implications for action/next steps
15:10-15:30	 Perspectives on sustainability and transition from aid at country level. Bruno Rivalan, Director, Action Santé Mondiale/Global Health Advocates
15:30-15:40	Feedback and implications for action/next steps
15:40-16:10	COFFEE BREAK
Chair /moder	ator: Bruno Rivalan
Chair /moder 16:10-16:30	Regional perspectives
	 Regional perspectives Camilo Cid, Advisor, Health Economics & Financing, PAHO /WHO Regional
	 Regional perspectives Camilo Cid, Advisor, Health Economics & Financing, PAHO /WHO Regional Office for the Americas Awad Mataria, Regional Adviser, Health Economics & Financing,
16:10-16:30	 Regional perspectives Camilo Cid, Advisor, Health Economics & Financing, PAHO /WHO Regional Office for the Americas Awad Mataria, Regional Adviser, Health Economics & Financing, EMRO/WHO Regional Office for the Eastern Mediterranean

(For day 2 agenda, please see next page)

3. Rethinking the discussion on sustainability and transition 9:009:15 Recap from day one - Clare Dickinson Chair /moderator: Triin Habicht 09:15-10:15 Raising revenues while managing expenditure growth: a balancing act for sustainability and transition Joe Kutzin, Health Financing Coordinator, WHO Ajay Tandon, Lead Economist, World Bank Discussant: Bill Savedoff Senior Fellow Centre for Global Development 10:15-11:00 Feedback and implications for action/next steps 11:00-11:30 COFFEE BREAK Chair /moderator: Matthias Reinicke, European Commission 11:30-12:30 Transition for institution strengthening towards UHC • Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos David Clarke WHO legal frameworks and UHC • Gilles Forte Strengthening procurement and pharmaceutical systems Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates 12:30-13:00 Feedback and implications for action/next steps 13:00-14:00 14:00-14:30 Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap • Objectives of IHP for UHC2030 Scope of the STWG 14:30-15:00 Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants </th <th colspan="2">DAY 2: SUSTAINABILITY, TRANSITION AND UNIT OF ANALYSIS AND PRIORITY AREAS OF WORK</th>	DAY 2: SUSTAINABILITY, TRANSITION AND UNIT OF ANALYSIS AND PRIORITY AREAS OF WORK		
Chair /moderator:Triin Habicht09:15-10:15Raising revenues while managing expenditure growth: a balancing act for sustainability and transition 	3. Rethinking the discussion on sustainability and transition		
09:15-10:15Raising revenues while managing expenditure growth: a balancing act for sustainability and transition• Joe Kutzin, Health Financing Coordinator, WHO • Ajay Tandon, Lead Economist, World Bank10:15-11:00Feedback and implications for action/next steps11:00-11:30COFFEE BREAKChair /moderator:Matthias Reinicke, European Commission11:30-12:30Transition for institution strengthening towards UHC • Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos • David Clarke WHO legal frameworks and UHC • Gilles Forte Strengthening procurement and pharmaceutical systems • Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates12:30-13:00Feedback and implications for action/next steps13:00-14:00LUNCHDiscussion on priority work areas – agenda for action • Objectives of IHP for UHC2030 • Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG • Review of ideas so far for STWG activities from discussion • Constituents' views and consensus on suggested activities15:00-15:15Discussion on scope of each activity area: • Ito for Uh to develop, next steps)16:15-17:00Feedback/summary on each activity area			
sustainability and transitionJoe Kutzin, Health Financing Coordinator, WHOAjay Tandon, Lead Economist, World BankDiscussant: Bill Savedoff Senior Fellow Centre for Global Development10:15-11:00Feedback and implications for action/next steps11:00-11:30COFFEE BREAKChair /moderator: Matthias Reinicke, European Commission11:30-12:30Transition for institution strengthening towards UHC• Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos• David Clarke WHO legal frameworks and UHC• Gilles Forte Strengthening procurement and pharmaceutical systems• Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates12:30-13:00Feedback and implications for action/next steps13:00-14:00LUNCHDiscussion on priority work areas – agenda for actionPurpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap• Objectives of IHP for UHC2030 • Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG15:00-15:15COFFEE BREAK15:00-15:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area	Chair /moder	ator: Triin Habicht	
 Joe Kutzin, Health Financing Coordinator, WHO Ajay Tandon, Lead Economist, World Bank Discussant: Bill Savedoff Senior Fellow Centre for Global Development 10:15-11:00 Feedback and implications for action/next steps 11:00-11:30 COFFEE BREAK Chair /moderator: Matthias Reinicke, European Commission 11:30-12:30 Transition for institution strengthening towards UHC Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos David Clarke WHO legal frameworks and UHC Gilles Forte Strengthening procurement and pharmaceutical systems Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates 12:30-13:00 Feedback and implications for action/next steps 13:00-14:00 LUNCH Discussion on priority work areas – agenda for action UHC2030 core team to recap Objectives of IHP for UHC2030 Scope of the STWG Scope of the STWG Scope of the STWG Review of ideas so far for STWG activities from discussion Feedback on added value of the STWG Review of ideas so far for STWG activities from discussion Constituents' views and consensus on suggested activities 15:15-16:15 Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps) 16:15-17:00 Feedback/summary on each activity area 	09:15-10:15	Raising revenues while managing expenditure growth: a balancing act for	
 Ajay Tandon, Lead Economist, World Bank Discussant: Bill Savedoff Senior Fellow Centre for Global Development 10:15-11:00 Feedback and implications for action/next steps 11:00-11:30 COFFEE BREAK Chair /moderator: Matthias Reinicke, European Commission 11:30-12:30 Transition for institution strengthening towards UHC Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos David Clarke WHO legal frameworks and UHC Gilles Forte Strengthening procurement and pharmaceutical systems Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates 12:30-13:00 Feedback and implications for action/next steps 13:00-14:00 UUNCH Discussion or priority work areas – agenda for action UHC2030 core team to recap Objectives of IHP for UHC2030 Scope of the STWG Scope of the STWG 14:30-15:00 Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants Feedback on added value of the STWG Review of ideas so far for STWG activities from discussion Constituents' views and consensus on suggested activities Sicussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps) 		·	
Discussant: Bill Savedoff Senior Fellow Centre for Global Development10:15-11:00Feedback and implications for action/next steps11:00-11:30COFFEE BREAKChair /moderator: Matthias Reinicke, European Commission11:30-12:30Transition for institution strengthening towards UHC• Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos• David Clarke WHO legal frameworks and UHC• Gilles Forte Strengthening procurement and pharmaceutical systems• Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates13:00-14:00LUNCHDiscussion on priority work areas – agenda for action14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap• Objectives of IHP for UHC2030 • Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)			
10:15-11:00Feedback and implications for action/next steps11:00-11:30COFFEE BREAKChair /moderator:Matthias Reinicke, European Commission11:30-12:30Transition for institution strengthening towards UHC• Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos • David Clarke WHO legal frameworks and UHC• Gilles Forte Strengthening procurement and pharmaceutical systems • Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates12:30-13:00Feedback and implications for action/next steps13:00-14:00LUNCHDiscussion on priority work areas – agenda for action14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap • Objectives of IHP for UHC2030 • Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG • Review of ideas so far for STWG activities from discussion • Constituents' views and consensus on suggested activities15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area		Ajay Tandon, Lead Economist, World Bank	
11:00-11:30COFFEE BREAKChair /moderator:Matthias Reinicke, European Commission11:30-12:30Transition for institution strengthening towards UHC•Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos•David Clarke WHO legal frameworks and UHC•Gilles Forte Strengthening procurement and pharmaceutical systems•Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates12:30-13:00Feedback and implications for action/next steps13:00-14:00LUNCHDiscussion on priority work areas – agenda for actionDiscussion on priority work areas – agenda for action14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap • Objectives of IHP for UHC2030 • Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)		Discussant: Bill Savedoff Senior Fellow Centre for Global Development	
Chair /moderator:Matthias Reinicke, European Commission11:30-12:30Transition for institution strengthening towards UHC11:30-12:30Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silosDavid Clarke WHO legal frameworks and UHCGilles Forte Strengthening procurement and pharmaceutical systemsBruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates12:30-13:00Feedback and implications for action/next steps13:00-14:00LUNCHDiscussion on priority work areas – agenda for action14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap0 Objectives of IHP for UHC2030Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants14:30-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)	10:15-11:00	Feedback and implications for action/next steps	
11:30-12:30Transition for institution strengthening towards UHC•Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos•David Clarke WHO legal frameworks and UHC•Gilles Forte Strengthening procurement and pharmaceutical systems•Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates12:30-13:00Feedback and implications for action/next steps13:00-14:00LUNCHDiscussion on priority work areas – agenda for action14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap • Objectives of IHP for UHC2030 • Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG14:30-15:15COFFEE BREAK15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area	<u>11:00-11:30</u>	COFFEE BREAK	
 Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos David Clarke WHO legal frameworks and UHC Gilles Forte Strengthening procurement and pharmaceutical systems Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates 12:30-13:00 Feedback and implications for action/next steps 13:00-14:00 LUNCH Discussion or priority work areas – agenda for action UHC2030 core team to recap Objectives of IHP for UHC2030 Scope of the STWG 14:30-15:00 Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants Feedback on added value of the STWG Review of ideas so far for STWG activities from discussion Constituents' views and consensus on suggested activities 15:00-15:15 COFFEE BREAK Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps) 16:15-17:00 	Chair /moder	ator: Matthias Reinicke, European Commission	
 David Clarke WHO legal frameworks and UHC Gilles Forte Strengthening procurement and pharmaceutical systems Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates 12:30-13:00 Feedback and implications for action/next steps 13:00-14:00 LUNCH Discussion on priority work areas – agenda for action 14:00-14:30 Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap Objectives of IHP for UHC2030 Scope of the STWG 14:30-15:00 Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants Feedback on added value of the STWG Review of ideas so far for STWG activities from discussion Constituents' views and consensus on suggested activities 15:00-15:15 COFFEE BREAK Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps) 16:15-17:00 Feedback/summary on each activity area 	11:30-12:30	Transition for institution strengthening towards UHC	
 Gilles Forte Strengthening procurement and pharmaceutical systems Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates 12:30-13:00 Feedback and implications for action/next steps 13:00-14:00 LUNCH Discussion on priority work areas – agenda for action 14:00-14:30 Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap Objectives of IHP for UHC2030 Scope of the STWG 14:30-15:00 Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants Feedback on added value of the STWG Review of ideas so far for STWG activities from discussion Constituents' views and consensus on suggested activities 15:00-15:15 COFFEE BREAK Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps) 16:15-17:00 Feedback/summary on each activity area 		Susan Sparkes, WHO Cross Programmatic Inefficiencies breaking the silos	
• Bruno Rivalan, Director of Action Santé Mondiale/Global Health Advocates12:30-13:00Feedback and implications for action/next steps13:00-14:00LUNCHDiscussion on priority work areas – agenda for action14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap • Objectives of IHP for UHC2030 • Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG • Review of ideas so far for STWG activities from discussion • Constituents' views and consensus on suggested activities15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area		David Clarke WHO legal frameworks and UHC	
Advocates12:30-13:00Feedback and implications for action/next steps13:00-14:00LUNCHDiscussion on priority work areas – agenda for action14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap Objectives of IHP for UHC2030Scope of the STWG 14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants Feedback on added value of the STWGReview of ideas so far for STWG activities from discussion Constituents' views and consensus on suggested activities15:10-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of 		Gilles Forte Strengthening procurement and pharmaceutical systems	
12:30-13:00Feedback and implications for action/next steps13:00-14:00LUNCHDiscussion on priority work areas – agenda for action14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap 		Bruno Rivalan, Director of Action Santé Mondiale/Global Health	
13:00-14:00LUNCHDiscussion on priority work areas – agenda for action14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap • Objectives of IHP for UHC2030 • Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG • Review of ideas so far for STWG activities from discussion • Constituents' views and consensus on suggested activities15:10-15:15COFFEE BREAK Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area		Advocates	
Discussion on priority work areas – agenda for action14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap • Objectives of IHP for UHC2030 • Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG • Review of ideas so far for STWG activities from discussion • Constituents' views and consensus on suggested activities15:00-15:15COFFEE BREAK Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area	12:30-13:00	Feedback and implications for action/next steps	
14:00-14:30Purpose of afternoon session: to clarify role and start to develop work-plan UHC2030 core team to recap • Objectives of IHP for UHC2030 • Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG • Review of ideas so far for STWG activities from discussion • Constituents' views and consensus on suggested activities15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area	13:00-14:00	LUNCH	
UHC2030 core team to recap• Objectives of IHP for UHC2030• Scope of the STWG14:30-15:00Identifying STWG added value and areas of workFacilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants• Feedback on added value of the STWG• Review of ideas so far for STWG activities from discussion• Constituents' views and consensus on suggested activities15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area	Discussion on	priority work areas – agenda for action	
 Objectives of IHP for UHC2030 Scope of the STWG Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants Feedback on added value of the STWG Review of ideas so far for STWG activities from discussion Constituents' views and consensus on suggested activities 15:00-15:15 COFFEE BREAK Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps) 16:15-17:00 	14:00-14:30	Purpose of afternoon session: to clarify role and start to develop work-plan	
Scope of the STWG14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG • Review of ideas so far for STWG activities from discussion • Constituents' views and consensus on suggested activities15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area		UHC2030 core team to recap	
14:30-15:00Identifying STWG added value and areas of work Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants • Feedback on added value of the STWG • Review of ideas so far for STWG activities from discussion • Constituents' views and consensus on suggested activities15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area		Objectives of IHP for UHC2030	
Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants• Feedback on added value of the STWG• Review of ideas so far for STWG activities from discussion• Constituents' views and consensus on suggested activities15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area		Scope of the STWG	
Facilitators: Veronica Walford & Clare Dickinson IHP for UHC2030 consultants• Feedback on added value of the STWG• Review of ideas so far for STWG activities from discussion• Constituents' views and consensus on suggested activities15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area	14:30-15:00	Identifying STWG added value and areas of work	
 Feedback on added value of the STWG Review of ideas so far for STWG activities from discussion Constituents' views and consensus on suggested activities 15:00-15:15 COFFEE BREAK Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps) 16:15-17:00 Feedback/summary on each activity area 	1 1100 10100		
 Review of ideas so far for STWG activities from discussion Constituents' views and consensus on suggested activities 15:00-15:15 COFFEE BREAK Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps) 16:15-17:00 Feedback/summary on each activity area 			
• Constituents' views and consensus on suggested activities15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area			
15:00-15:15COFFEE BREAK15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area			
15:15-16:15Discussion on scope of each activity area: (to focus on 4 points: purpose of proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area	15:00-15:15		
proposed activity, who to involve, how to develop, next steps)16:15-17:00Feedback/summary on each activity area			
16:15-17:00 Feedback/summary on each activity area			
	16:15-17:00		